565 related articles for article (PubMed ID: 23735867)
21. An observational study on bloodstream extended-spectrum beta-lactamase infection in critical care unit: incidence, risk factors and its impact on outcome.
Nasa P; Juneja D; Singh O; Dang R; Singh A
Eur J Intern Med; 2012 Mar; 23(2):192-5. PubMed ID: 22284253
[TBL] [Abstract][Full Text] [Related]
22. Impact of empirical treatment in extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. bacteremia. A multicentric cohort study.
Peralta G; Lamelo M; Alvarez-García P; Velasco M; Delgado A; Horcajada JP; Montero M; Roiz MP; Fariñas MC; Alonso J; Martínez LM; Gutiérrez-Macías A; Alava JA; Rodríguez A; Fleites A; Navarro V; Sirvent E; Capdevila JA;
BMC Infect Dis; 2012 Oct; 12():245. PubMed ID: 23038999
[TBL] [Abstract][Full Text] [Related]
23. Risk factors for and outcomes of healthcare-associated infection due to extended-spectrum beta-lactamase-producing Escherichia coli or Klebsiella pneumoniae in Thailand.
Apisarnthanarak A; Kiratisin P; Saifon P; Kitphati R; Dejsirilert S; Mundy LM
Infect Control Hosp Epidemiol; 2007 Jul; 28(7):873-6. PubMed ID: 17564993
[TBL] [Abstract][Full Text] [Related]
24. Impact of a clonal outbreak of extended-spectrum β-lactamase-producing Klebsiella pneumoniae in the development and evolution of bloodstream infections by K. pneumoniae and Escherichia coli: an 11 year experience in Oxfordshire, UK.
Webster DP; Young BC; Morton R; Collyer D; Batchelor B; Turton JF; Maharjan S; Livermore DM; Bejon P; Cookson BD; Bowler IC
J Antimicrob Chemother; 2011 Sep; 66(9):2126-35. PubMed ID: 21693458
[TBL] [Abstract][Full Text] [Related]
25. [Risk factors associated with the isolation of extended spectrum betalactamases producing Escherichia coli or Klebsiella pneumoniae in a tertiary care hospital in Colombia].
Jiménez A; Alvarado A; Gómez F; Carrero G; Fajardo C
Biomedica; 2014 Apr; 34 Suppl 1():16-22. PubMed ID: 24968032
[TBL] [Abstract][Full Text] [Related]
26. Impact of Extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae on the outcome of community-onset bacteremic urinary tract infections.
Yang YS; Ku CH; Lin JC; Shang ST; Chiu CH; Yeh KM; Lin CC; Chang FY
J Microbiol Immunol Infect; 2010 Jun; 43(3):194-9. PubMed ID: 21291846
[TBL] [Abstract][Full Text] [Related]
27. Bacteremic pneumonia caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: Appropriateness of empirical treatment matters.
Cheng WL; Hsueh PR; Lee CC; Li CW; Li MJ; Chang CM; Lee NY; Ko WC
J Microbiol Immunol Infect; 2016 Apr; 49(2):208-15. PubMed ID: 25070279
[TBL] [Abstract][Full Text] [Related]
28. Nosocomial extended-spectrum beta-lactamase-producing Klebsiella pneumoniae bacteremia in hemodialysis patients and the implications for antibiotic therapy.
Yang CC; Wu CH; Lee CT; Liu HT; Chen JB; Chiu CH; Chen CH; Chuang FR
Int J Infect Dis; 2014 Nov; 28():3-7. PubMed ID: 25200093
[TBL] [Abstract][Full Text] [Related]
29. Comparison of Predictors and Mortality Between Bloodstream Infections Caused by ESBL-Producing Escherichia coli and ESBL-Producing Klebsiella pneumoniae.
Scheuerman O; Schechner V; Carmeli Y; Gutiérrez-Gutiérrez B; Calbo E; Almirante B; Viale PL; Oliver A; Ruiz-Garbajosa P; Gasch O; Gozalo M; Pitout J; Akova M; Peña C; Molina J; Hernández-Torres A; Venditti M; Prim N; Origüen J; Bou G; Tacconelli E; Tumbarello M; Hamprecht A; Karaiskos I; de la Calle C; Pérez F; Schwaber MJ; Bermejo J; Lowman W; Hsueh PR; Navarro-San Francisco C; Bonomo RA; Paterson DL; Pascual A; Rodríguez-Baño J;
Infect Control Hosp Epidemiol; 2018 Jun; 39(6):660-667. PubMed ID: 29618394
[TBL] [Abstract][Full Text] [Related]
30. Risk factors for bloodstream infections caused by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae.
Quirante OF; Cerrato SG; Pardos SL
Braz J Infect Dis; 2011; 15(4):370-6. PubMed ID: 21861009
[TBL] [Abstract][Full Text] [Related]
31. Risk factors for multidrug resistance in nosocomial bacteremia caused by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae.
Park SY; Kang CI; Joo EJ; Ha YE; Wi YM; Chung DR; Peck KR; Lee NY; Song JH
Microb Drug Resist; 2012 Oct; 18(5):518-24. PubMed ID: 22742454
[TBL] [Abstract][Full Text] [Related]
32. Carbapenem therapy for bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae.
Lee NY; Huang WH; Tsui KC; Hsueh PR; Ko WC
Diagn Microbiol Infect Dis; 2011 May; 70(1):150-3. PubMed ID: 21398070
[TBL] [Abstract][Full Text] [Related]
33. Extended-spectrum beta-lactamase-producing Klebsiella pneumoniae hospital acquired bacteremia. Risk factors and clinical outcome.
Panhotra BR; Saxena AK; Al-Ghamdi AM
Saudi Med J; 2004 Dec; 25(12):1871-6. PubMed ID: 15711657
[TBL] [Abstract][Full Text] [Related]
34. Escherichia coli and Klebsiella pneumoniae bacteremia in patients with neutropenic fever: factors associated with extended-spectrum β-lactamase production and its impact on outcome.
Kim SH; Kwon JC; Choi SM; Lee DG; Park SH; Choi JH; Yoo JH; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS
Ann Hematol; 2013 Apr; 92(4):533-41. PubMed ID: 23161391
[TBL] [Abstract][Full Text] [Related]
35. [Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in Spanish hospitals: 2nd multicenter study (GEIH-BLEE project, 2006)].
Angel Díaz M; Ramón Hernández J; Martínez-Martínez L; Rodríguez-Baño J; Pascual A;
Enferm Infecc Microbiol Clin; 2009 Nov; 27(9):503-10. PubMed ID: 19329230
[TBL] [Abstract][Full Text] [Related]
36. Extended-spectrum beta-lactamases and clinical outcomes: current data.
Ramphal R; Ambrose PG
Clin Infect Dis; 2006 Apr; 42 Suppl 4():S164-72. PubMed ID: 16544267
[TBL] [Abstract][Full Text] [Related]
37. [Prevalence of extended-spectrum beta-lactamases in nosocomial Escherichia coli and Klebsiella spp. strains isolated from blood cultures].
Zarakolu P; Metan G; Hasçelik G; Akova M
Mikrobiyol Bul; 2007 Oct; 41(4):579-84. PubMed ID: 18173077
[TBL] [Abstract][Full Text] [Related]
38. Comparative effectiveness of flomoxef versus carbapenems in the treatment of bacteraemia due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae with emphasis on minimum inhibitory concentration of flomoxef: a retrospective study.
Lee CH; Su LH; Chen FJ; Tang YF; Li CC; Chien CC; Liu JW
Int J Antimicrob Agents; 2015 Dec; 46(6):610-5. PubMed ID: 26387064
[TBL] [Abstract][Full Text] [Related]
39. Fluoroquinolone therapy for bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae.
Lo CL; Lee CC; Li CW; Li MC; Hsueh PR; Lee NY; Ko WC
J Microbiol Immunol Infect; 2017 Jun; 50(3):355-361. PubMed ID: 26423244
[TBL] [Abstract][Full Text] [Related]
40. Epidemiology and clinical features of community-onset bacteremia caused by extended-spectrum β-lactamase-producing Klebsiella pneumoniae.
Lee JA; Kang CI; Joo EJ; Ha YE; Kang SJ; Park SY; Chung DR; Peck KR; Ko KS; Lee NY; Song JH
Microb Drug Resist; 2011 Jun; 17(2):267-73. PubMed ID: 21388296
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
